Amyris relaunch

mit kleiner posi,zum beobachten,und jetzt 120%+ich werd nich mehr☹  

hättest mehr mum haben sollen, so , wie ich,alles was ich noch hatte, 3000euro  

"Schaut euch nur mal den Chart an, der zeigt schon seit längerem an, was jetzt gerade passiert"

Am 20.09.2016 hab ich das geschrieben. Wäre da schon liebend gern reingegangen. Aber voll investiert. In AEZS und Biodel. Also jammern kann man da nicht. Aber der Chart war schon im September so was von perfekt bei Amyris. Solche Chancen darf man sich eigentlich nicht entgehen lassen!  

schon klar,bin auch in Biodel,dazu meine Hauptposi in True Leaf,Paion und ein paar Explorer,da war nichtmehr soviel für Amyris über  

Aber ich jammer ja nicht,grün überwiegt  

Privacy


About


Contributors


Contact




     



The Cerbat Gem    


.

Headlines


Markets


M&A


Analysts’ Updates


Earnings


Health & Biotech


Technology

..




 


 



 
Amyris Inc. - Get News & Ratings Daily

Enter your email address below to get the latest news and analysts' ratings for Amyris Inc. with our FREE daily email newsletter:

   





 


Recent Market News
Leerink Swann Weighs in on Shire PLC’s Q3 2016 Earnings (SHPG)
Equities Analysts Offer Predictions for Whiting Petroleum Corp.’s Q3 2016 Earnings (WLL)
Wolverine World Wide Inc. to Post Q3 2016 Earnings of $0.49 Per Share, B. Riley Forecasts (WWW)
Q3 2016 EPS Estimates for Robert Half International Inc. (RHI) Decreased by Analyst
XL Group PLC (XL) Forecasted to Post Q3 2016 Earnings of $0.38 Per Share
Brokers Offer Predictions for Ur Energy Inc.’s Q3 2016 Earnings (URG)
Leerink Swann Equities Analysts Lift Earnings Estimates for UnitedHealth Group Inc. (UNH)
Research Analysts Offer Predictions for Pinnacle West Capital Corp.’s Q3 2016 Earnings (PNW)
Q3 2016 EPS Estimates for Universal American Corp. Reduced by Leerink Swann (UAM)
Q3 2016 Earnings Estimate for Time Warner Inc. Issued By Wedbush (TWX)
Copper Mountain Mining Co.. (CUM) to Post Q3 2016 Earnings of $0.00 Per Share, National Bank Financial Forecasts
Stewart Information Services Corp. (STC) to Post Q3 2016 Earnings of $0.95 Per Share, Langen Mcalenn Forecasts
RBC Capital Markets Increases Yahoo Inc. (YHOO) Price Target to $45.00
DA Davidson Analysts Cut Earnings Estimates for Gildan Activewear Inc. (GIL)
Equities Analysts Set Expectations for Hallador Energy Co.’s FY2017 Earnings (HNRG)
FY2017 Earnings Estimate for Jack In The Box Inc. (JACK) Issued By SunTrust Banks
FY2017 EPS Estimates for Pfizer Inc. (PFE) Cut by Jefferies Group
FY2017 EPS Estimates for Southwest Gas Corp. (SWX) Raised by Analyst
MGIC Investment Corp. (MTG) Downgraded by Compass Point
Piper Jaffray Cos. Downgrades Sangamo BioSciences Inc. (SGMO) to Neutral






Amyris Inc. (AMRS) Major Shareholder (Mauritius) Pte Ltd Maxwell Sells 2,300,000 Shares of Stock

October 19th, 2016 -  By Jessica Moore - 0 comments








Amyris logoAmyris Inc. (NASDAQ:AMRS) major shareholder (Mauritius) Pte Ltd Maxwell sold 2,300,000 shares of the company’s stock in a transaction dated Monday, October 17th. The stock was sold at an average price of $0.83, for a total transaction of $1,909,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Amyris Inc. (NASDAQ:AMRS) opened at 1.08 on Wednesday. The company’s market cap is $253.82 million. The firm’s 50-day moving average is $0.55 and its 200 day moving average is $0.59. Amyris Inc. has a 1-year low of $0.31 and a 1-year high of $1.85.

Amyris (NASDAQ:AMRS) last released its earnings results on Thursday, August 4th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.06. The business earned $9.60 million during the quarter, compared to analysts’ expectations of $15.23 million. During the same quarter in the previous year, the business earned ($0.47) EPS. The business’s revenue for the quarter was up 23.1% on a year-over-year basis. Analysts predict that Amyris Inc. will post ($0.20) earnings per share for the current fiscal year.



 
A number of brokerages recently issued reports on AMRS. Zacks Investment Research cut shares of Amyris from a “buy” rating to a “hold” rating in a research note on Monday, September 5th. Singular Research reiterated a “buy” rating and issued a $2.80 price target on shares of Amyris in a research note on Wednesday, September 28th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $2.66.

A number of hedge funds have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. acquired a new stake in Amyris during the first quarter worth $269,000. Geode Capital Management LLC raised its position in shares of Amyris by 11.6% in the first quarter. Geode Capital Management LLC now owns 298,669 shares of the company’s stock valued at $331,000 after buying an additional 30,958 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock valued at $766,000 after buying an additional 311,142 shares in the last quarter. Institutional investors and hedge funds own 35.68% of the company’s stock.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

5 Day Chart for NASDAQ:AMRS






Receive News & Stock Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related stocks with our FREE daily email newsletter.
 

hast ja alles richtig gemacht mit deinen ivestitionen  

2,7% im minus, also geht es hier auch runter bis zum handelsbeginn von nas. und dann sehen wir, nochmal gewinnmitnahmen oder?  

Hi,
kannst Du bitte noch die Quelle / den Link angeben?
Danke und Gruß  

 

Amyris Inc. (AMRS) Lowered to Hold at Zacks Investment Research

October 20th, 2016 -  By Doug Wharley - 0 comments








Amyris Inc. logoZacks Investment Research cut shares of Amyris Inc. (NASDAQ:AMRS) from a buy rating to a hold rating in a report published on Wednesday morning.

According to Zacks, “Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. “

Separately, Singular Research reiterated a buy rating and set a $2.80 target price on shares of Amyris in a report on Wednesday, September 28th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $2.66.



 
Shares of Amyris (NASDAQ:AMRS) opened at 1.05 on Wednesday. The firm’s market cap is $246.77 million. Amyris has a 12 month low of $0.31 and a 12 month high of $1.85. The stock’s 50 day moving average is $0.57 and its 200 day moving average is $0.59.

Amyris (NASDAQ:AMRS) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.06. The business earned $9.60 million during the quarter, compared to analysts’ expectations of $15.23 million. The firm’s quarterly revenue was up 23.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.47) EPS. On average, analysts anticipate that Amyris will post ($0.20) earnings per share for the current fiscal year.

In other Amyris news, major shareholder (Mauritius) Pte Ltd Maxwell sold 2,300,000 shares of the company’s stock in a transaction that occurred on Monday, October 17th. The stock was sold at an average price of $0.83, for a total value of $1,909,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 48.70% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of AMRS. Geode Capital Management LLC raised its stake in Amyris by 11.6% in the first quarter. Geode Capital Management LLC now owns 298,669 shares of the company’s stock valued at $331,000 after buying an additional 30,958 shares in the last quarter. Vanguard Group Inc. raised its stake in Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock valued at $766,000 after buying an additional 311,142 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Amyris during the first quarter valued at about $269,000. 35.68% of the stock is currently owned by institutional investors and hedge funds.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
 

1 euro  

alles wird gut, nächste Woche gehts ab  

verschrieben, geschafft,  

hat das unternehmen früher bei Kursen 25 Euro die Marktkapitalisierung von 25 Milliarden Euro  

Hallo, wie kommst du auf solche absurden Zahlen(?) und wir wären selbst jetzt bei Kursen von 25 EUR nicht bei 25 Mrd €.

Aktuell 235 Mio outstanding Shares (lt.Bloomberg) wären bei 25 EUR knapp 6 Mrd EUR Marktkapitalisierung. Da hab ich genug Phantasie, dass wir diesen Wert im Lauf der nächsten 3 Jahre errreichen.

Wahrscheinlich eher die 6Mrd MK, als die 25 € im Kurs, da ein derartiger Expansionskurs auch durch die Ausgabe neuer Aktien unterfüttert sein will. Siehe Meldung von letzter Woche, als der Partner ein "..investment of up
to $20 million at $1.40 per share.." tätigte. (Dort stand der Kurs übrigends zuletzt im März diesen Jahres - hoffe ich im Lauf der nächsten Woche wieder zu erreichen.)

Ein kurzer Blick, 6 Jahre zurück: "...underwriting sources have revealed that Amyris Inc. will raise $84.8 million in its initial public offering of its common stock, pricing at $16 per share, well below its expected range of $18-$20 per share.

Overall, the IPO placed an overall valuation on the company of $680.6 million, ..."

42,8 Mio shares gab es also im Oktober 2010 - rechne mal gut mit 50 Mio Stück, dann ergäbe das eine damalige MK von 1.25 Mrd $ beim Kurs von 25$

http://www.biofuelsdigest.com/bdigest/2010/09/28/amyris-raises-84-8m-in-ipo-prices-at-16-well-below-expected-range/

Die wirklich alten AMRS Hasen mögen mich verbessern, bin erst seit September an Bord 

Schönen Sonntag noch! ​

 

haben grossewarenkette produzieren und verkaufen dinge aus heimatstoffen, holz, porzellan, bioprodukte usw.
Market News | Thu Oct 27, 2016 | 5:29am EDT

BRIEF-Guanfu Holdings' unit plans to invest $5 mln in Amyris
 












Oct 27 Guanfu Holdings Co Ltd

* Says unit plans to invest $5 million in Amyris

Source text in Chinese: bit.ly/2eUtPOw
 
Further company coverage: (Reporting by Hong Kong newsroom)
 

globalen pharmaunternehmen,nun der dritte im bunde und wer mag das sein,noch nicht
veröffentlicht

Amyris, Inc. (Nasdaq: AMRS), the industrial bioscience company, is pleased to announce it has entered into a research agreement with a commercial license option with one of the top 10 largest global pharmaceutical companies. Under the terms of the agreement, the collaboration will use Amyris's µPharmTM platform technology to develop a customized library of natural and natural-like compounds to test its partner’s target antibiotic therapeutic.

Nature has been a great source for therapeutics, ranging from antibiotics to statins that lower cholesterol levels; however, Nature's potential is often under-utilized due to scarcity or unavailability. Amyris's µPharm platform technology enables an integrated discovery and production process for therapeutic compounds. It not only provides access to scarce natural compounds, but also creates new diversity based on natural compound scaffolds.

“We’re pleased to have executed our second large µPharm collaboration during the second half of 2016 as planned,” said John Melo, Amyris President and CEO. “We are continuing to experience significant momentum in our business and within biopharma alone we have now executed agreements with three of the top companies in the industry, each leaders in their fields.”

"Adding another top pharmaceutical company partner to our collaboration portfolio demonstrates the robust growth opportunity we see in the space," said Cynthia Bryant, Amyris Senior Vice President Corporate Development & Collaborations. "The flexibility and power of Amyris’s technology platform can be harnessed for a variety of applications and within biopharma can open a new area of compounds that have never been accessible for new drug discovery."

Amyris will utilize the µPharm platform technology to develop a library of natural and natural-like compounds and test the efficacy of those compounds in vivo for hits against the identified target. This is a different approach than traditional high throughput screening, which typically applies thousands of chemical compounds in in vitro screens to find a drug candidate. Instead, the µPharm platform starts with the target to improve efficiency, identifies candidate natural compound structures, and then creates diversity around those structures for in vivo testing.
 

EMERYVILLE, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Biossance™, the consumer beauty brand from Amyris, Inc. (NASDAQ:AMRS), today announced its planned launch in Sephora's retail stores where the brand's expansive line of high-performance skin care products will be available to consumers. The rollout to initial participating stores will begin in February 2017 and coincide with launching on Sephora online. Additional in-store and online marketing activities with Sephora to highlight the Biossance brand shortly following launch are planned.

http://investors.amyris.com/releasedetail.cfm?ReleaseID=996315  

sephora, läuft das, wahnsinnnnnn
 

siehe finanznachrichten.de  

EPS of -$0.07 misses by $0.01.

Revenue of $26.54M (+209.0% Y/Y) misses by $7.07M

hatte mehr erwartet :-(  

habe viele andere qart. gesehen und hast du gelesen, alle neuabschlüsse noch nicht drin, lese und du wirst sehen  

für cca. 1 mill. aber mehrere hegdefonds haben zukekauft, nicht in der menge, wie vom grossaktionär verkauft wurde, aber immerhin, versteh , wer will, will wissen , wer den aktionär verärgert hat  

und erklärung warum der seit tagen immer noch regelmäßig shares raushaut?